News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Sales reflect continued strong growth in oncology and vaccines
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
International Business is expected to register double-digit growth in constant currency terms
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Subscribe To Our Newsletter & Stay Updated
